肠复方对晚期大肠癌患者外周血CK20 mRNA、端粒酶表达的影响

发布时间：2018-01-02 23:23

本文关键词：肠复方对晚期大肠癌患者外周血CK20 mRNA、端粒酶表达的影响　出处：《中医杂志》2017年11期 　论文类型：期刊论文

【摘要】：目的观察肠复方治疗晚期大肠癌的临床疗效。方法选择晚期大肠癌患者60例,随机分为治疗组和对照组各30例,另选择健康体检者10人设为正常组。对照组给予对症支持治疗,治疗组在对照组基础上给予肠复方,每日1剂。两组均治疗并随访1年,计算患者半年及1年生存率。采集正常组外周血,治疗组及对照组治疗前及治疗2个月时采集外周血,采用荧光定量PCR检测外周血中细胞角蛋白20(CK 20)mRNA表达,并采用免疫吸附法检测端粒酶表达量;治疗2个月后通过CT检查评估瘤体控制率;治疗后观察疾病进展时间。结果治疗2个月后治疗组、对照组瘤体控制率分别为66.67%、26.67%,治疗组高于对照组(P=0.002)。治疗组及对照组患者外周血CK20 mRNA、端粒酶表达量显著高于正常组(P0.01)。治疗组治疗2个月外周血CK20 mRNA、端粒酶表达较治疗前显著降低(P0.01),对照组治疗2个月外周血CK20 mRNA、端粒酶表达较治疗前显著升高(P0.01);治疗2个月治疗组外周血CK20 mRNA、端粒酶表达显著低于对照组(P0.01)。治疗组疾病进展时间明显长于对照组(P0.01)。治疗组1年期生存率明显高于对照组(P=0.022)。结论肠复方治疗晚期大肠癌有效,能提高瘤体控制率,延长疾病进展时间,提高远期生存获益,并降低患者外周血中端粒酶及CK20 mRNA表达。
[Abstract]:Objective to observe the clinical effect of Changfang in the treatment of advanced colorectal cancer. Methods 60 patients with advanced colorectal cancer were randomly divided into treatment group and control group (n = 30 each). In addition, 10 healthy persons were selected as normal group. The control group was treated with symptomatic support therapy, the treatment group was given intestinal compound on the basis of the control group, and the two groups were treated and followed up for 1 year. Six months and one year survival rate were calculated. Peripheral blood was collected from normal group, treatment group and control group before treatment and 2 months after treatment. The expression of cytokeratin CK20 mRNA in peripheral blood was detected by fluorescence quantitative PCR and telomerase expression was detected by immunosorbent assay. After 2 months of treatment, the tumor control rate was evaluated by CT. Results after 2 months of treatment, the control rate of tumor in the control group was 66.67% and 26.67% respectively. CK20 mRNA in peripheral blood of patients in treatment group and control group was higher than that in control group. The expression of telomerase was significantly higher than that of normal group (P 0.01). The expression of telomerase mRNA in peripheral blood of treatment group was significantly lower than that before treatment (P 0.01). In the control group, the expression of telomerase in peripheral blood CK20 mRNAs was significantly higher than that before treatment for 2 months (P 0.01). CK20 mRNA in peripheral blood of treatment group for 2 months. The expression of telomerase was significantly lower than that of the control group (P 0.01). The disease progression time in the treatment group was significantly longer than that in the control group (P 0.01). The 1-year survival rate in the treatment group was significantly higher than that in the control group (P 0.022). Conclusion intestinal compound is effective in the treatment of advanced colorectal cancer. It can improve the tumor control rate, prolong the time of disease progression, improve the long-term survival benefit, and reduce the expression of telomerase and CK20 mRNA in peripheral blood of patients.
【作者单位】：湖南中医药大学研究生院;湖南省肿瘤医院;
【基金】：湖南省中医药管理局项目(2012140) 中南大学湘雅临床大数据系统建设项目(2013003)
【分类号】：R273
【正文快照】： 大肠癌(colorectal cancer,CR)包括结肠癌和直肠癌,是常见的恶性肿瘤之一。据《2015年中国肿瘤登记年报》[1]数据显示,全国恶性肿瘤发病率中大肠癌排第三位。相关报道称,早期根治手术后的5年生存率可高达90%,而有转移的患者,其5年的生存率则低于10%[2]。研究显示,中医药在肿瘤

【相似文献】